Antidepressant withdrawal: When and how to taper antidepressants
Antidepressants can be a powerful tool for treating mental health conditions like depression and anxiety, and they often work best when combined with talk therapy. Therapists help individuals develop effective strategies to reduce stress and address the underlying causes of mental health issues. Once you feel better, you might consider stopping antidepressants, but this decision should be made carefully with your physician or therapist’s support. When trying to stop medication, many people face difficulties with withdrawal symptoms, anxiety, and a rebound of depression. At least half of those on antidepressants experience challenges during the tapering process. This article outlines some reasons for withdrawal symptoms and offers strategies to minimize the risks.
What is antidepressant withdrawal?
Antidepressant withdrawal can happen when someone stops taking their medication. The body adjusts to the drug, making it hard for your brain and body to adapt to lower levels of medication. About half of the people who discontinue antidepressants experience trouble sleeping, strange physical sensations, and mood swings. Some report feeling electric pulses in the head, sometimes called ‘brain zaps,’ and intense physical and emotional restlessness (akathisia). The risk of withdrawal and the severity of symptoms are higher with certain medications, such as fluoxetine, or for those taking higher doses of SSRIs or SNRIs, and for individuals who have been on medication for many years.
Factors affecting medication withdrawal
Many factors can influence the speed of medication clearance from your body and the risk of withdrawal:
-
- Fat-solubility – Drugs that are better absorbed by fat tissue (lipophilicity) are eliminated more gradually, reducing the risk of withdrawal.
- Half–life – Drugs that are eliminated more quickly (shorter half-lives) can cause rapid changes in antidepressant levels, especially if you accidentally skip a dose; the drug’s blood concentrations might become too low.
- Drug class – Serotonin and norepinephrine reuptake inhibitors (SNRIs) are more difficult to stop than SSRIs. Trazodone is a Serotonin Antagonist and Reuptake Inhibitor (SARI) that has a better risk profile and is easier to taper.
- Your DNA –Your drug metabolic profile is shaped by genetic variations that can make you a “fast” or “slow” metabolizer. Special genetic tests, called pharmacogenetics, can reveal how quickly your body clears antidepressants and other medications. In many cases, for those who have had to try multiple antidepressants to find one that works, these tests can help explain why they didn’t respond to one drug or experienced adverse side effects from another. A pharmacogenetic profile could assist your doctor and pharmacist in assessing your risk of withdrawal, which is higher for people with altered metabolism (i.e., for fast or slow metabolizers).
- Your age – For people with reduced liver function due to age or past infections, the rate of drug metabolism is also slower. Typically, people with reduced liver function require a lower maintenance dose, making it easier to taper.
Which antidepressants are harder to stop?
The following table highlights the withdrawal risks associated with some common antidepressants.
| Drug Name | Risk of Withdrawal | Drug Class | Main Metabolizing Enzyme |
|---|---|---|---|
| Duloxetine | Higher | SNRI | CYP1A2, CYP2D6 |
| Fluvoxamine | Higher | SSRI | CYP2D6, CYP1A2 |
| Levomilnacipran | Higher | SNRI | Primarily eliminated by kidneys, CYP3A4 minor |
| Mirtazapine | Higher | NaSSA | CYP1A2, CYP2D6, CYP3A4 |
| Paroxetine | Higher | SSRI | CYP2D6 |
| Desvenlafaxine | Higher | SNRI | minimal CYP involvement |
| Venlafaxine | Higher | SNRI | CYP2D6, CYP2C19 |
| Citalopram and escitalopram | Moderate | SSRI | CYP2C19 |
| Fluoxetine | Moderate | SSRI | CYP2D6 |
| Sertraline | Moderate | SSRI | CYP2B6, CYP2C19 |
| Vortioxetine | Moderate | CYP2D6 | |
| Trazodone | Low | SARI | CYP3A4 |
| Bupropion | Unknown | NDRI | CYP2B6 |
How can you reduce the risk and severity of antidepressant withdrawal symptoms?
Go slowly
Rapid antidepressant tapering over one or two months is linked to a significantly higher risk of relapse. Gradually tapering the medication over several months helps reduce withdrawal symptoms. I.e., the slower, the better. The dose should be decreased in very small steps, tailored to your initial drug dose and metabolic profile – that is, how quickly your body metabolizes the medication.
Clinician support and monitoring
Consult with your psychiatrist whether it is the right time for you to start tapering your medication and set up regular talk sessions to monitor your progress (every 2-4 weeks) to support you during this challenging period.
Learn your drug metabolism
A pharmacogenetic report to assess how quickly your body eliminates the antidepressants and other medications you are taking. This information is essential for a pharmacist to determine how quickly you can taper and how to adjust the doses of other medications you are taking.
Decide on a tapering strategy
A pharmacist can recommend the mode of dose tapering which has a significant effect.
A ‘linear’ dose reduction model is standard, but it tends to cause issues. For example, a sertraline step-down schedule from 200 mg/day over five months was unsuccessful for nearly 60% of patients who took the medication for about nine months.
The “hyperbolic” taper regimen is designed to mimic the inverse process of the antidepressant response curve when medications are initiated. In the hyperbolic model, the daily dose reduction steps become progressively smaller. This can be achieved by decreasing the dose by a specific percentage, such as 10% per month. Clinical studies show that the hyperbolic regimen reduces the risk of withdrawal, but it can take up to a year to discontinue a high-risk drug like venlafaxine.
Consider customized drug dosing and formulations: since splitting hard pills can make fractional doses tricky, tailored antidepressant doses or liquid formulations prepared by compounding pharmacies (such as www.pharmacy.ca) help ensure precise dosing.
Get a medication reminder app – it is vital to stick to the drug schedule as advised by the pharmacist. Missing doses or taking medication at the wrong times can affect drug blood levels and worsen anxiety and depression symptoms.
Stay active
Double down on physical exercise, yoga, meditation and other activities to strengthen your body and spirit.
Dealing with setbacks
If you notice a decline in your mental health, feel free to pause or revert to a higher dose based on your comfort. Discuss recent medication changes with your pharmacist, as some supplements and medicines can influence antidepressant levels in your blood and lead to a setback. Seek help from a psychotherapist or psychiatrist and book additional talk therapy sessions. Consult your doctor to determine when it is safe to resume tapering after your symptoms have stabilized.
Summary
- Withdrawal symptoms occur in almost half of people when they stop an antidepressant.
- The higher the dose and the longer the treatment duration, the greater the risk of withdrawal symptoms during standard tapering.
- Some individuals may need several months or even a year of gradual (hyperbolic) tapering to minimize distressing or dangerous symptoms.
- Pharmacogenetic testing can help identify your metabolic profile, and an experienced pharmacist can create a tapering plan to lower your risk of setbacks.
- A compounding pharmacy can prepare specific doses for tapering or offer a liquid formulation for more precise medication adjustments.
- Consult with a pharmacist if you start or stop another medication, especially if it could affect the metabolism of the antidepressant.
- Engaging in talk therapy, physical activity, and meditation can support your stability during the tapering process.
Selected references
Stopping antidepressants safely Therapeutic Initiative (University of British Columbia)
Henssler J et al., Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024 Jul;11(7):526-535
Kendrick T et al., Internet and telephone intervention to support patients discontinuing long-term antidepressants in primary care: the REDUCE research programme including RCT. Southampton (UK): National Institute for Health and Care Research; 2025 Jul.
O’Brien D et al., A systematic review of manipulations to pharmaceutical dosage forms used in psychotropic tapering plans.. Br J Clin Pharmacol. 2025 Jul;91(7):1899-1913.
